Intravenous Solutions Market By Type (Partial Parenteral Nutrition, Total Parenteral Nutrition), By Composition (Carbohydrates, Vitamins and Minerals, Single Dose Amino Acids, Parenteral Lipid Emulsion, Others), By End Users (Hospitals and Clinics, Ambula

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,380	318 Pages	Allied Market Research	July, 2022	ALMR17464555

Best Price Guarantee
Price	from $4,380
Length	318 Pages
Publisher	Allied Market Research
Published Date	July, 2022
SKU	ALMR17464555

Intravenous Solutions Market By Type (Partial Parenteral Nutrition, Total Parenteral Nutrition), By Composition (Carbohydrates, Vitamins and Minerals, Single Dose Amino Acids, Parenteral Lipid Emulsion, Others), By End Users (Hospitals and Clinics, Ambulatory Surgery Centers, Home care settings): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global intravenous solutions market was valued at $11,857.7 million in 2021, and is projected to reach $26,558.4 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.

IV solutions are specially formulated liquids that are injected into a vein to prevent or treat dehydration. They are used in people of all ages who are sick, injured and dehydrated from exercise, heat and those who are undergoing surgery. Intravenous rehydration is a simple, safe and common procedure with a low risk of complications. They are injected into a person’s veins through an IV (intravenous) tube. They prevent or treat dehydration and electrolyte imbalances. There are two types of intravenous fluids that include, crystalloid solutions and colloids. Crystalloid solutions contain small dissolved molecules that pass easily from the bloodstream into tissues and cells. Some of the examples of it include normal saline, which is salt in water, and D5W, which is dextrose (sugar) in water. Moreover, lactated Ringer’s, which contains sodium, chloride, potassium, calcium and lactate can also be included in the crystalloid solutions. Colloids are large molecules that can’t easily pass through cell membranes and are more likely to stay in the blood vessels. Some of the examples include albumin and hetastarch solutions.

The global intravenous solutions market is anticipated to show significant market growth during the forecast period, owing to increase in the prevalence of malnutrition, the faster response time and higher efficacy associated with intravenous solution therapy and surge in the geriatric population. Furthermore, increase in prevalence of cancer and rise in natality rate are considerably contributing toward the market growth. However, lack of experienced healthcare professionals and complications of intravenous administration therapy are negatively impacting the market growth. Conversely, the high growth opportunities in emerging markets offers the lucrative opportunities for the growth of the market.

The intravenous solutions market is segmented on the basis of type, composition, end user, and region. By type, the market is classified into partial parenteral nutrition and total parenteral nutrition. Furthermore, the partial parenteral nutrition is sub-classified as pediatric and adult. Also, the total parenteral nutrition is sub-classified as pediatric and adult. By composition, the market is classified into carbohydrates, vitamins and minerals, single dose amino acids, parenteral lipid emulsion and others. By end user, the market is classified into hospitals and clinics, ambulatory surgery centers, home care settings. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in the report include Amanta Healthcare Ltd., Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eurolife Healthcare Pvt Ltd, Fresenius Kabi AG, Grifols S.A., Henry Schein Inc., ICU Medical, Inc., JW Life Science, OtsUKa Pharmaceutical Co.,Ltd., Pfizer, Inc., Salius Pharma Private Limited , Sichuan Kelun Pharmaceutical Co. Ltd., Soxa Formulations & Research Pvt. Ltd., Vifor Pharma Management Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the intravenous solutions market analysis from 2021 to 2031 to identify the prevailing intravenous solutions market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the intravenous solutions market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global intravenous solutions market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Partial Parenteral Nutrition
Age Group
Pediatric
Adult
Total Parenteral Nutrition
Age Group
Pediatric
Adult

By Composition

Carbohydrates
Vitamins and Minerals
Single Dose Amino Acids
Parenteral Lipid Emulsion
Others

By End Users

Hospitals and Clinics
Ambulatory Surgery Centers
Home care settings

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Venezuela
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Amanta Healthcare Ltd.
Axa Parenterals Ltd.
B. Braun Melsungen AG
Baxter International Inc.
Becton, Dickinson and Company
Eurolife Healthcare Pvt Ltd.
Fresenius Kabi AG
Grifols S.A
Henry Schein Inc.
ICU Medical, Inc.
JW Life Science
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
Salius Pharma Private Limited
Sichuan Kelun Pharmaceutical Co. Ltd
Soxa Formulations & Research (Pvt.) Ltd.
Vifor Pharma Management Ltd.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key market segments; 1.3.Key benefits to the stakeholders; 1.4.Research Methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Porter’s five forces analysis; 3.4.Top player positioning; 3.5.Market dynamics; 3.5.1.Drivers; 3.5.2.Restraints; 3.5.3.Opportunities; 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: INTRAVENOUS SOLUTIONS MARKET, BY TYPE: 4.1 Overview; 4.1.1 Market size and forecast; 4.2 Partial Parenteral Nutrition; 4.2.1 Key market trends, growth factors and opportunities; 4.2.2 Market size and forecast, by region; 4.2.3 Market analysis by country; 4.2.4 Partial Parenteral Nutrition Intravenous Solutions Market by Age Group; 4.3 Total Parenteral Nutrition; 4.3.1 Key market trends, growth factors and opportunities; 4.3.2 Market size and forecast, by region; 4.3.3 Market analysis by country; 4.3.4 Total Parenteral Nutrition Intravenous Solutions Market by Age Group
CHAPTER 5: INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION: 5.1 Overview; 5.1.1 Market size and forecast; 5.2 Carbohydrates; 5.2.1 Key market trends, growth factors and opportunities; 5.2.2 Market size and forecast, by region; 5.2.3 Market analysis by country; 5.3 Vitamins and Minerals; 5.3.1 Key market trends, growth factors and opportunities; 5.3.2 Market size and forecast, by region; 5.3.3 Market analysis by country; 5.4 Single Dose Amino Acids; 5.4.1 Key market trends, growth factors and opportunities; 5.4.2 Market size and forecast, by region; 5.4.3 Market analysis by country; 5.5 Parenteral Lipid Emulsion; 5.5.1 Key market trends, growth factors and opportunities; 5.5.2 Market size and forecast, by region; 5.5.3 Market analysis by country; 5.6 Others; 5.6.1 Key market trends, growth factors and opportunities; 5.6.2 Market size and forecast, by region; 5.6.3 Market analysis by country
CHAPTER 6: INTRAVENOUS SOLUTIONS MARKET, BY END USERS: 6.1 Overview; 6.1.1 Market size and forecast; 6.2 Hospitals and Clinics; 6.2.1 Key market trends, growth factors and opportunities; 6.2.2 Market size and forecast, by region; 6.2.3 Market analysis by country; 6.3 Ambulatory Surgery Centers; 6.3.1 Key market trends, growth factors and opportunities; 6.3.2 Market size and forecast, by region; 6.3.3 Market analysis by country; 6.4 Home care settings; 6.4.1 Key market trends, growth factors and opportunities; 6.4.2 Market size and forecast, by region; 6.4.3 Market analysis by country
CHAPTER 7: INTRAVENOUS SOLUTIONS MARKET, BY REGION: 7.1 Overview; 7.1.1 Market size and forecast; 7.2 North America; 7.2.1 Key trends and opportunities; 7.2.2 North America Market size and forecast, by Type; 7.2.3 North America Market size and forecast, by Composition; 7.2.4 North America Market size and forecast, by End Users; 7.2.5 North America Market size and forecast, by country; 7.2.5.1 U.S.; 7.2.5.1.1 Market size and forecast, by Type; 7.2.5.1.2 Market size and forecast, by Composition; 7.2.5.1.3 Market size and forecast, by End Users; 7.2.5.2 Canada; 7.2.5.2.1 Market size and forecast, by Type; 7.2.5.2.2 Market size and forecast, by Composition; 7.2.5.2.3 Market size and forecast, by End Users; 7.2.5.3 Mexico; 7.2.5.3.1 Market size and forecast, by Type; 7.2.5.3.2 Market size and forecast, by Composition; 7.2.5.3.3 Market size and forecast, by End Users; 7.3 Europe; 7.3.1 Key trends and opportunities; 7.3.2 Europe Market size and forecast, by Type; 7.3.3 Europe Market size and forecast, by Composition; 7.3.4 Europe Market size and forecast, by End Users; 7.3.5 Europe Market size and forecast, by country; 7.3.5.1 Germany; 7.3.5.1.1 Market size and forecast, by Type; 7.3.5.1.2 Market size and forecast, by Composition; 7.3.5.1.3 Market size and forecast, by End Users; 7.3.5.2 France; 7.3.5.2.1 Market size and forecast, by Type; 7.3.5.2.2 Market size and forecast, by Composition; 7.3.5.2.3 Market size and forecast, by End Users; 7.3.5.3 UK; 7.3.5.3.1 Market size and forecast, by Type; 7.3.5.3.2 Market size and forecast, by Composition; 7.3.5.3.3 Market size and forecast, by End Users; 7.3.5.4 Italy; 7.3.5.4.1 Market size and forecast, by Type; 7.3.5.4.2 Market size and forecast, by Composition; 7.3.5.4.3 Market size and forecast, by End Users; 7.3.5.5 Spain; 7.3.5.5.1 Market size and forecast, by Type; 7.3.5.5.2 Market size and forecast, by Composition; 7.3.5.5.3 Market size and forecast, by End Users; 7.3.5.6 Rest of Europe; 7.3.5.6.1 Market size and forecast, by Type; 7.3.5.6.2 Market size and forecast, by Composition; 7.3.5.6.3 Market size and forecast, by End Users; 7.4 Asia-Pacific; 7.4.1 Key trends and opportunities; 7.4.2 Asia-Pacific Market size and forecast, by Type; 7.4.3 Asia-Pacific Market size and forecast, by Composition; 7.4.4 Asia-Pacific Market size and forecast, by End Users; 7.4.5 Asia-Pacific Market size and forecast, by country; 7.4.5.1 Japan; 7.4.5.1.1 Market size and forecast, by Type; 7.4.5.1.2 Market size and forecast, by Composition; 7.4.5.1.3 Market size and forecast, by End Users; 7.4.5.2 China; 7.4.5.2.1 Market size and forecast, by Type; 7.4.5.2.2 Market size and forecast, by Composition; 7.4.5.2.3 Market size and forecast, by End Users; 7.4.5.3 India; 7.4.5.3.1 Market size and forecast, by Type; 7.4.5.3.2 Market size and forecast, by Composition; 7.4.5.3.3 Market size and forecast, by End Users; 7.4.5.4 Australia; 7.4.5.4.1 Market size and forecast, by Type; 7.4.5.4.2 Market size and forecast, by Composition; 7.4.5.4.3 Market size and forecast, by End Users; 7.4.5.5 South Korea; 7.4.5.5.1 Market size and forecast, by Type; 7.4.5.5.2 Market size and forecast, by Composition; 7.4.5.5.3 Market size and forecast, by End Users; 7.4.5.6 Taiwan; 7.4.5.6.1 Market size and forecast, by Type; 7.4.5.6.2 Market size and forecast, by Composition; 7.4.5.6.3 Market size and forecast, by End Users; 7.4.5.7 Rest of Asia-Pacific; 7.4.5.7.1 Market size and forecast, by Type; 7.4.5.7.2 Market size and forecast, by Composition; 7.4.5.7.3 Market size and forecast, by End Users; 7.5 LAMEA; 7.5.1 Key trends and opportunities; 7.5.2 LAMEA Market size and forecast, by Type; 7.5.3 LAMEA Market size and forecast, by Composition; 7.5.4 LAMEA Market size and forecast, by End Users; 7.5.5 LAMEA Market size and forecast, by country; 7.5.5.1 Brazil; 7.5.5.1.1 Market size and forecast, by Type; 7.5.5.1.2 Market size and forecast, by Composition; 7.5.5.1.3 Market size and forecast, by End Users; 7.5.5.2 Turkey; 7.5.5.2.1 Market size and forecast, by Type; 7.5.5.2.2 Market size and forecast, by Composition; 7.5.5.2.3 Market size and forecast, by End Users; 7.5.5.3 Venezuela; 7.5.5.3.1 Market size and forecast, by Type; 7.5.5.3.2 Market size and forecast, by Composition; 7.5.5.3.3 Market size and forecast, by End Users; 7.5.5.4 Saudi Arabia; 7.5.5.4.1 Market size and forecast, by Type; 7.5.5.4.2 Market size and forecast, by Composition; 7.5.5.4.3 Market size and forecast, by End Users; 7.5.5.5 South Africa; 7.5.5.5.1 Market size and forecast, by Type; 7.5.5.5.2 Market size and forecast, by Composition; 7.5.5.5.3 Market size and forecast, by End Users; 7.5.5.6 Rest of LAMEA; 7.5.5.6.1 Market size and forecast, by Type; 7.5.5.6.2 Market size and forecast, by Composition; 7.5.5.6.3 Market size and forecast, by End Users
CHAPTER 8: COMPANY LANDSCAPE: 8.1. Introduction; 8.2. Top winning strategies; 8.3. Product Mapping of Top 10 Player; 8.4. Competitive Dashboard; 8.5. Competitive Heatmap; 8.6. Key developments
CHAPTER 9: COMPANY PROFILES: 9.1 Amanta Healthcare Ltd.; 9.1.1 Company overview; 9.1.2 Company snapshot; 9.1.3 Operating business segments; 9.1.4 Product portfolio; 9.1.5 Business performance; 9.1.6 Key strategic moves and developments; 9.2 Axa Parenterals Ltd.; 9.2.1 Company overview; 9.2.2 Company snapshot; 9.2.3 Operating business segments; 9.2.4 Product portfolio; 9.2.5 Business performance; 9.2.6 Key strategic moves and developments; 9.3 B. Braun Melsungen AG; 9.3.1 Company overview; 9.3.2 Company snapshot; 9.3.3 Operating business segments; 9.3.4 Product portfolio; 9.3.5 Business performance; 9.3.6 Key strategic moves and developments; 9.4 Baxter International Inc.; 9.4.1 Company overview; 9.4.2 Company snapshot; 9.4.3 Operating business segments; 9.4.4 Product portfolio; 9.4.5 Business performance; 9.4.6 Key strategic moves and developments; 9.5 Becton, Dickinson and Company; 9.5.1 Company overview; 9.5.2 Company snapshot; 9.5.3 Operating business segments; 9.5.4 Product portfolio; 9.5.5 Business performance; 9.5.6 Key strategic moves and developments; 9.6 Eurolife Healthcare Pvt Ltd.; 9.6.1 Company overview; 9.6.2 Company snapshot; 9.6.3 Operating business segments; 9.6.4 Product portfolio; 9.6.5 Business performance; 9.6.6 Key strategic moves and developments; 9.7 Fresenius Kabi AG; 9.7.1 Company overview; 9.7.2 Company snapshot; 9.7.3 Operating business segments; 9.7.4 Product portfolio; 9.7.5 Business performance; 9.7.6 Key strategic moves and developments; 9.8 Grifols S.A; 9.8.1 Company overview; 9.8.2 Company snapshot; 9.8.3 Operating business segments; 9.8.4 Product portfolio; 9.8.5 Business performance; 9.8.6 Key strategic moves and developments; 9.9 Henry Schein Inc.; 9.9.1 Company overview; 9.9.2 Company snapshot; 9.9.3 Operating business segments; 9.9.4 Product portfolio; 9.9.5 Business performance; 9.9.6 Key strategic moves and developments; 9.10 ICU Medical, Inc.; 9.10.1 Company overview; 9.10.2 Company snapshot; 9.10.3 Operating business segments; 9.10.4 Product portfolio; 9.10.5 Business performance; 9.10.6 Key strategic moves and developments; 9.11 JW Life Science; 9.11.1 Company overview; 9.11.2 Company snapshot; 9.11.3 Operating business segments; 9.11.4 Product portfolio; 9.11.5 Business performance; 9.11.6 Key strategic moves and developments; 9.12 Otsuka Pharmaceutical Co., Ltd.; 9.12.1 Company overview; 9.12.2 Company snapshot; 9.12.3 Operating business segments; 9.12.4 Product portfolio; 9.12.5 Business performance; 9.12.6 Key strategic moves and developments; 9.13 Pfizer, Inc.; 9.13.1 Company overview; 9.13.2 Company snapshot; 9.13.3 Operating business segments; 9.13.4 Product portfolio; 9.13.5 Business performance; 9.13.6 Key strategic moves and developments; 9.14 Salius Pharma Private Limited; 9.14.1 Company overview; 9.14.2 Company snapshot; 9.14.3 Operating business segments; 9.14.4 Product portfolio; 9.14.5 Business performance; 9.14.6 Key strategic moves and developments; 9.15 Sichuan Kelun Pharmaceutical Co. Ltd; 9.15.1 Company overview; 9.15.2 Company snapshot; 9.15.3 Operating business segments; 9.15.4 Product portfolio; 9.15.5 Business performance; 9.15.6 Key strategic moves and developments; 9.16 Soxa Formulations & Research (Pvt.) Ltd.; 9.16.1 Company overview; 9.16.2 Company snapshot; 9.16.3 Operating business segments; 9.16.4 Product portfolio; 9.16.5 Business performance; 9.16.6 Key strategic moves and developments; 9.17 Vifor Pharma Management Ltd.; 9.17.1 Company overview; 9.17.2 Company snapshot; 9.17.3 Operating business segments; 9.17.4 Product portfolio; 9.17.5 Business performance; 9.17.6 Key strategic moves and developments
LIST OF TABLES: TABLE 1. GLOBAL INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 2. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR PARTIAL PARENTERAL NUTRITION, BY REGION, 2021-2031 ($MILLION); TABLE 3. INTRAVENOUS SOLUTIONS MARKET FOR PARTIAL PARENTERAL NUTRITION, BY COUNTRY, 2021-2031 ($MILLION); TABLE 4. GLOBAL PARTIAL PARENTERAL NUTRITION INTRAVENOUS SOLUTIONS MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 5. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR TOTAL PARENTERAL NUTRITION, BY REGION, 2021-2031 ($MILLION); TABLE 6. INTRAVENOUS SOLUTIONS MARKET FOR TOTAL PARENTERAL NUTRITION, BY COUNTRY, 2021-2031 ($MILLION); TABLE 7. GLOBAL TOTAL PARENTERAL NUTRITION INTRAVENOUS SOLUTIONS MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 8. GLOBAL INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 9. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR CARBOHYDRATES, BY REGION, 2021-2031 ($MILLION); TABLE 10. INTRAVENOUS SOLUTIONS MARKET FOR CARBOHYDRATES, BY COUNTRY, 2021-2031 ($MILLION); TABLE 11. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR VITAMINS AND MINERALS, BY REGION, 2021-2031 ($MILLION); TABLE 12. INTRAVENOUS SOLUTIONS MARKET FOR VITAMINS AND MINERALS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 13. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR SINGLE DOSE AMINO ACIDS, BY REGION, 2021-2031 ($MILLION); TABLE 14. INTRAVENOUS SOLUTIONS MARKET FOR SINGLE DOSE AMINO ACIDS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 15. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR PARENTERAL LIPID EMULSION, BY REGION, 2021-2031 ($MILLION); TABLE 16. INTRAVENOUS SOLUTIONS MARKET FOR PARENTERAL LIPID EMULSION, BY COUNTRY, 2021-2031 ($MILLION); TABLE 17. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION); TABLE 18. INTRAVENOUS SOLUTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 19. GLOBAL INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 20. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($MILLION); TABLE 21. INTRAVENOUS SOLUTIONS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 22. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021-2031 ($MILLION); TABLE 23. INTRAVENOUS SOLUTIONS MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 24. INTRAVENOUS SOLUTIONS MARKET SIZE, FOR HOME CARE SETTINGS, BY REGION, 2021-2031 ($MILLION); TABLE 25. INTRAVENOUS SOLUTIONS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 26. INTRAVENOUS SOLUTIONS MARKET, BY REGION, 2021-2031 ($MILLION); TABLE 27. NORTH AMERICA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 28. NORTH AMERICA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 29. NORTH AMERICA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 30. NORTH AMERICA INTRAVENOUS SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 31. U.S. INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 32. U.S. INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 33. U.S. INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 34. CANADA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 35. CANADA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 36. CANADA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 37. MEXICO INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 38. MEXICO INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 39. MEXICO INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 40. EUROPE INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 41. EUROPE INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 42. EUROPE INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 43. EUROPE INTRAVENOUS SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 44. GERMANY INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 45. GERMANY INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 46. GERMANY INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 47. FRANCE INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 48. FRANCE INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 49. FRANCE INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 50. UK INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 51. UK INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 52. UK INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 53. ITALY INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 54. ITALY INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 55. ITALY INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 56. SPAIN INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 57. SPAIN INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 58. SPAIN INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 59. REST OF EUROPE INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 60. REST OF EUROPE INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 61. REST OF EUROPE INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 62. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 63. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 64. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 65. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 66. JAPAN INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 67. JAPAN INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 68. JAPAN INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 69. CHINA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 70. CHINA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 71. CHINA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 72. INDIA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 73. INDIA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 74. INDIA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 75. AUSTRALIA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 76. AUSTRALIA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 77. AUSTRALIA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 78. SOUTH KOREA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 79. SOUTH KOREA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 80. SOUTH KOREA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 81. TAIWAN INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 82. TAIWAN INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 83. TAIWAN INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 84. REST OF ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 85. REST OF ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 86. REST OF ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 87. LAMEA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 88. LAMEA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 89. LAMEA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 90. LAMEA INTRAVENOUS SOLUTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 91. BRAZIL INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 92. BRAZIL INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 93. BRAZIL INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 94. TURKEY INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 95. TURKEY INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 96. TURKEY INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 97. VENEZUELA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 98. VENEZUELA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 99. VENEZUELA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 100. SAUDI ARABIA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 101. SAUDI ARABIA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 102. SAUDI ARABIA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 103. SOUTH AFRICA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 104. SOUTH AFRICA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 105. SOUTH AFRICA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 106. REST OF LAMEA INTRAVENOUS SOLUTIONS MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 107. REST OF LAMEA INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION, 2021-2031 ($MILLION); TABLE 108. REST OF LAMEA INTRAVENOUS SOLUTIONS MARKET, BY END USERS, 2021-2031 ($MILLION); TABLE 109.AMANTA HEALTHCARE LTD.: COMPANY SNAPSHOT; TABLE 110.AMANTA HEALTHCARE LTD.: OPERATING SEGMENTS; TABLE 111.AMANTA HEALTHCARE LTD.: PRODUCT PORTFOLIO; TABLE 112.AMANTA HEALTHCARE LTD.: NET SALES,; TABLE 113.AMANTA HEALTHCARE LTD.: KEY STRATERGIES; TABLE 114.AXA PARENTERALS LTD.: COMPANY SNAPSHOT; TABLE 115.AXA PARENTERALS LTD.: OPERATING SEGMENTS; TABLE 116.AXA PARENTERALS LTD.: PRODUCT PORTFOLIO; TABLE 117.AXA PARENTERALS LTD.: NET SALES,; TABLE 118.AXA PARENTERALS LTD.: KEY STRATERGIES; TABLE 119.B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT; TABLE 120.B. BRAUN MELSUNGEN AG: OPERATING SEGMENTS; TABLE 121.B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO; TABLE 122.B. BRAUN MELSUNGEN AG: NET SALES,; TABLE 123.B. BRAUN MELSUNGEN AG: KEY STRATERGIES; TABLE 124.BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT; TABLE 125.BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS; TABLE 126.BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO; TABLE 127.BAXTER INTERNATIONAL INC.: NET SALES,; TABLE 128.BAXTER INTERNATIONAL INC.: KEY STRATERGIES; TABLE 129.BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT; TABLE 130.BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS; TABLE 131.BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO; TABLE 132.BECTON, DICKINSON AND COMPANY: NET SALES,; TABLE 133.BECTON, DICKINSON AND COMPANY: KEY STRATERGIES; TABLE 134.EUROLIFE HEALTHCARE PVT LTD.: COMPANY SNAPSHOT; TABLE 135.EUROLIFE HEALTHCARE PVT LTD.: OPERATING SEGMENTS; TABLE 136.EUROLIFE HEALTHCARE PVT LTD.: PRODUCT PORTFOLIO; TABLE 137.EUROLIFE HEALTHCARE PVT LTD.: NET SALES,; TABLE 138.EUROLIFE HEALTHCARE PVT LTD.: KEY STRATERGIES; TABLE 139.FRESENIUS KABI AG: COMPANY SNAPSHOT; TABLE 140.FRESENIUS KABI AG: OPERATING SEGMENTS; TABLE 141.FRESENIUS KABI AG: PRODUCT PORTFOLIO; TABLE 142.FRESENIUS KABI AG: NET SALES,; TABLE 143.FRESENIUS KABI AG: KEY STRATERGIES; TABLE 144.GRIFOLS S.A: COMPANY SNAPSHOT; TABLE 145.GRIFOLS S.A: OPERATING SEGMENTS; TABLE 146.GRIFOLS S.A: PRODUCT PORTFOLIO; TABLE 147.GRIFOLS S.A: NET SALES,; TABLE 148.GRIFOLS S.A: KEY STRATERGIES; TABLE 149.HENRY SCHEIN INC.: COMPANY SNAPSHOT; TABLE 150.HENRY SCHEIN INC.: OPERATING SEGMENTS; TABLE 151.HENRY SCHEIN INC.: PRODUCT PORTFOLIO; TABLE 152.HENRY SCHEIN INC.: NET SALES,; TABLE 153.HENRY SCHEIN INC.: KEY STRATERGIES; TABLE 154.ICU MEDICAL, INC.: COMPANY SNAPSHOT; TABLE 155.ICU MEDICAL, INC.: OPERATING SEGMENTS; TABLE 156.ICU MEDICAL, INC.: PRODUCT PORTFOLIO; TABLE 157.ICU MEDICAL, INC.: NET SALES,; TABLE 158.ICU MEDICAL, INC.: KEY STRATERGIES; TABLE 159.JW LIFE SCIENCE: COMPANY SNAPSHOT; TABLE 160.JW LIFE SCIENCE: OPERATING SEGMENTS; TABLE 161.JW LIFE SCIENCE: PRODUCT PORTFOLIO; TABLE 162.JW LIFE SCIENCE: NET SALES,; TABLE 163.JW LIFE SCIENCE: KEY STRATERGIES; TABLE 164.OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT; TABLE 165.OTSUKA PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS; TABLE 166.OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO; TABLE 167.OTSUKA PHARMACEUTICAL CO., LTD.: NET SALES,; TABLE 168.OTSUKA PHARMACEUTICAL CO., LTD.: KEY STRATERGIES; TABLE 169.PFIZER, INC.: COMPANY SNAPSHOT; TABLE 170.PFIZER, INC.: OPERATING SEGMENTS; TABLE 171.PFIZER, INC.: PRODUCT PORTFOLIO; TABLE 172.PFIZER, INC.: NET SALES,; TABLE 173.PFIZER, INC.: KEY STRATERGIES; TABLE 174.SALIUS PHARMA PRIVATE LIMITED: COMPANY SNAPSHOT; TABLE 175.SALIUS PHARMA PRIVATE LIMITED: OPERATING SEGMENTS; TABLE 176.SALIUS PHARMA PRIVATE LIMITED: PRODUCT PORTFOLIO; TABLE 177.SALIUS PHARMA PRIVATE LIMITED: NET SALES,; TABLE 178.SALIUS PHARMA PRIVATE LIMITED: KEY STRATERGIES; TABLE 179.SICHUAN KELUN PHARMACEUTICAL CO. LTD: COMPANY SNAPSHOT; TABLE 180.SICHUAN KELUN PHARMACEUTICAL CO. LTD: OPERATING SEGMENTS; TABLE 181.SICHUAN KELUN PHARMACEUTICAL CO. LTD: PRODUCT PORTFOLIO; TABLE 182.SICHUAN KELUN PHARMACEUTICAL CO. LTD: NET SALES,; TABLE 183.SICHUAN KELUN PHARMACEUTICAL CO. LTD: KEY STRATERGIES; TABLE 184.SOXA FORMULATIONS & RESEARCH (PVT.) LTD.: COMPANY SNAPSHOT; TABLE 185.SOXA FORMULATIONS & RESEARCH (PVT.) LTD.: OPERATING SEGMENTS; TABLE 186.SOXA FORMULATIONS & RESEARCH (PVT.) LTD.: PRODUCT PORTFOLIO; TABLE 187.SOXA FORMULATIONS & RESEARCH (PVT.) LTD.: NET SALES,; TABLE 188.SOXA FORMULATIONS & RESEARCH (PVT.) LTD.: KEY STRATERGIES; TABLE 189.VIFOR PHARMA MANAGEMENT LTD.: COMPANY SNAPSHOT; TABLE 190.VIFOR PHARMA MANAGEMENT LTD.: OPERATING SEGMENTS; TABLE 191.VIFOR PHARMA MANAGEMENT LTD.: PRODUCT PORTFOLIO; TABLE 192.VIFOR PHARMA MANAGEMENT LTD.: NET SALES,; TABLE 193.VIFOR PHARMA MANAGEMENT LTD.: KEY STRATERGIES
LIST OF FIGURES: FIGURE 1.INTRAVENOUS SOLUTIONS MARKET SEGMENTATION; FIGURE 2.INTRAVENOUS SOLUTIONS MARKET,2021-2031; FIGURE 3.INTRAVENOUS SOLUTIONS MARKET,2021-2031; FIGURE 4. TOP INVESTMENT POCKETS, BY REGION; FIGURE 5.PORTER FIVE-1; FIGURE 6.PORTER FIVE-2; FIGURE 7.PORTER FIVE-3; FIGURE 8.PORTER FIVE-4; FIGURE 9.PORTER FIVE-5; FIGURE 10.TOP PLAYER POSITIONING; FIGURE 11.INTRAVENOUS SOLUTIONS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 12.INTRAVENOUS SOLUTIONS MARKET,BY TYPE,2021(%); FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PARTIAL PARENTERAL NUTRITION INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TOTAL PARENTERAL NUTRITION INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 15.INTRAVENOUS SOLUTIONS MARKET,BY COMPOSITION,2021(%); FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CARBOHYDRATES INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 17.COMPARATIVE SHARE ANALYSIS OF VITAMINS AND MINERALS INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SINGLE DOSE AMINO ACIDS INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 19.COMPARATIVE SHARE ANALYSIS OF PARENTERAL LIPID EMULSION INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 21.INTRAVENOUS SOLUTIONS MARKET,BY END USERS,2021(%); FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND CLINICS INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 23.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGERY CENTERS INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOME CARE SETTINGS INTRAVENOUS SOLUTIONS MARKET,2021-2031(%); FIGURE 25.INTRAVENOUS SOLUTIONS MARKET BY REGION,2021; FIGURE 26.U.S. INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 27.CANADA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 28.MEXICO INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 29.GERMANY INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 30.FRANCE INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 31.UK INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 32.ITALY INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 33.SPAIN INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 34.REST OF EUROPE INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 35.JAPAN INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 36.CHINA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 37.INDIA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 38.AUSTRALIA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 39.SOUTH KOREA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 40.TAIWAN INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 41.REST OF ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 42.BRAZIL INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 43.TURKEY INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 44.VENEZUELA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 45.SAUDI ARABIA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 46.SOUTH AFRICA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 47.REST OF LAMEA INTRAVENOUS SOLUTIONS MARKET,2021-2031($MILLION); FIGURE 48. TOP WINNING STRATEGIES, BY YEAR; FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT; FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY; FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 52.COMPETITIVE DASHBOARD; FIG

PDF E-mail From Publisher:	$5,769
Data Pack/Excel E-mail From Publisher:	$4,380
PDF (1-5 users):	$6,630
Global Site License Fulfilled by Publisher:	$10,500

Show additional purchase options...

Research Assistance

US: 800.298.5699

Int'l: +1.240.747.3093

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Intravenous Solutions Market By Type (Partial Parenteral Nutrition, Total Parenteral Nutrition), By Composition (Carbohydrates, Vitamins and Minerals, Single Dose Amino Acids, Parenteral Lipid Emulsion, Others), By End Users (Hospitals and Clinics, Ambula

Intravenous Solutions Market - By Type (Total, Peripheral Parenteral Nutrition), Composition (Carbohydrates, Vitamins & Minerals, Single-dose Amino Acids, Parenteral Lipid Emulsion), Age Group, Application, End-user, Global Forecast, 2024 - 2032

Japan Intravenous Solutions Market By Product (Total Parenteral Nutrition and Peripheral Parenteral Nutrition), By Nutrients (Carbohydrates, Vitamins & Minerals, Single-dose Amino Acids, Parenteral Lipid Emulsion and Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Intravenous Solutions Market Report by Type (Partial Parenteral Nutrition, Total Parenteral Nutrition), Nutrients (Carbohydrates, Salts and Electrolytes, Minerals, Vitamins, Amino Acids), and Region 2024-2032

Europe Parenteral Nutrition Market Forecast to 2030 - Regional Analysis - by Nutrient Type (Single Dose Amino Acid Solution, Parenteral Lipid Emulsion, Carbohydrates, Trace Elements, and Vitamins and Minerals) and End User (Hospitals, Clinics, and Others)

Research Assistance

Other tasks